List view / Grid view
3 April 2014 | By Daiichi Sankyo
Daiichi Sankyo Co., Ltd. and University of California, San Francisco announced that they have established a drug discovery collaboration focused on developing novel therapeutics and molecular diagnostics for multiple neurodegenerative diseases...
1 April 2014 | By Daiichi Sankyo Company
First patient enrolled in largest planned phase 3 study evaluating a novel oral antico-agulant in non-valvular atrial fibrillation patients undergoing electrical cardioversion...
25 March 2014 | By Daiichi Sankyo
Daiichi Sankyo Company, Limited announced its TaNeDS (Take a New challenge for Drug diScovery) collaborative drug discovery project for 2014...
24 March 2014 | By Daiichi Sankyo
Daiichi Sankyo Company, Limited announced late-breaking data from two pre-specified subgroup analyses of East Asian patients with non-valvular atrial fibrillation or venous thromboembolism enrolled in two phase 3 edoxaban studies...
24 March 2014 | By Daiichi Sankyo
Daiichi Sankyo Company, Limited announced that it has received approval from the Ministry of Health, Labour and Welfare in Japan for the antiplatelet agent Efient® 3.75mg/5mg Tablets...
19 March 2014 | By Daiichi Sankyo Company
Astellas Pharma Inc. and Daiichi Sankyo Company, Limited announced the companies would form a compound library sharing partnership for approximately 400,000 selected compounds...
7 March 2014 | By Daiichi Sankyo Company
Daiichi Sankyo Company, Limited announced in August 2011 that the group company Kitasato Daiichi Sankyo Vaccine Company, Limited was selected for the Japanese Ministry of Health, Labour and Welfare's cell culture vaccine production facility capacity building grant...
14 February 2014 | By Daiichi Sankyo Company
Norovirus is one of the leading causes of infectious gastroenteritis and the number of infected people reported is increasing both in Japan and globally...
24 January 2014 | By Daiichi Sankyo Company
Ranbaxy Laboratories Limited announced that the US FDA notified the company that it is prohibited from manufacturing and distributing active pharmaceutical ingredients from its facility in Toansa, India, for FDA-regulated drug products...
24 January 2014 | By Daiichi Sankyo
Daiichi Sankyo Company Ltd. announced that the US Food and Drug Administration has issued an import alert on January 23 on Active Pharmaceutical Ingredients...
9 January 2014 | By Daiichi Sankyo
Submission based on the two largest comparative phase 3 clinical trials of a novel oral anticoagulant in patients with non-valvular atrial fibrillation or symptomatic venous thromboembolism...
8 January 2014 | By Daiichi Sankyo
Virtici and Celdara Medical are affiliated, independent companies that build and develop pipelines of high potential therapeutic assets...
8 January 2014 | By Daiichi Sankyo
Daiichi Sankyo is seeking approval for edoxaban for the prevention of stroke and systemic embolic events in patients with non-valvular atrial fibrillation...
23 December 2013 | By Daiichi Sankyo Company
Daiichi Sankyo Company has received supplemental new drug application (sNDA) approval for Topotecin® injection 40 mg and 100 mg (irinotecan hydrochloride hydrate) for unresectable pancreatic cancer.
23 December 2013 | By Daiichi Sankyo Company
Daiichi Sankyo has received approval in Japan to market Inavir® Dry Powder Inhaler 20mg (generic name: Laninamivir Octanoate Hydrate)...
